How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/secondary-progressive-multiple-sclerosis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Secondary progressive multiple sclerosis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Secondary progressive multiple sclerosis (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Secondary progressive multiple sclerosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Mayzent	SIPONIMOD	Novartis	Sphingosine 1-phosphate Receptor Modulator [EPC]	Sphingosine 1-phosphate receptor 1	2019-01-01
Arzerra	Arzerra	GlaxoSmithKline		B-lymphocyte antigen CD20
Arzerra	HuMax-CD20	Glaxo Grp Ltd	CD20-directed Cytolytic Antibody	B-lymphocyte antigen CD20	2009-01-01
Mayzent	Mayzent	Novartis Pharmaceuticals		Sphingosine 1-phosphate receptor 2, Sphingosine 1-phosphate receptor 1, Sphingosine 1-phosphate receptor 3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Glaxo Grp Ltd · 1 drug in Secondary progressive multiple sclerosis
GlaxoSmithKline · 1 drug in Secondary progressive multiple sclerosis
Novartis · 1 drug in Secondary progressive multiple sclerosis
Novartis Pharmaceuticals · 1 drug in Secondary progressive multiple sclerosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Secondary progressive multiple sclerosis:

Cite this brief

Drug Landscape (2026). Secondary progressive multiple sclerosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/secondary-progressive-multiple-sclerosis. Accessed 2026-06-10.

Secondary progressive multiple sclerosis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing